Drug intelligence / Profile preview

gimatecan

Development stage: Phase 2
Lead developer: Lee's Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Gimatecan is an orally bioavailable, semi-synthetic lipophilic analogue of camptothecin, a quinoline alkaloid originally extracted from the Asian tree Camptotheca acuminata. It acts as a DNA topoisomerase I inhibitor, interfering with DNA replication and transcription in cancer cells, leading to cell death. Gimatecan has demonstrated antineoplastic and antiangiogenic activities and is being investigated for various solid tumors including ovarian cancer, small cell lung cancer, glioma, gastric cancer, and others. The drug was originally developed by Istituto Nazionale per lo Studio e la Cura dei Tumori and sigma-tau SpA; current developers include Lee's Pharmaceutical and Novartis[1][2][3][5].

Other names: gimatecan

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on gimatecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gimatecan.

Explore the full profile